Meeting
2018 ASCO Annual Meeting
Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009).
Authors
Andres Forero-Torres
University of Alabama at Birmingham, Birmingham, AL
Andres Forero-Torres , Heather Han , Elizabeth Claire Dees , Robert Wesolowski , Aditya Bardia , Peter Kabos , Rachel M. Layman , Janice M. Lu , Kenneth Alan Kern , Rachelle Perea , Kristen J. Pierce , Brett Houk , Nuzhat Pathan , Hope S. Rugo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02684032
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1040)
DOI
10.1200/JCO.2018.36.15_suppl.1040
Abstract #
1040
Poster Bd #
121
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC).
First Author: Robert Wesolowski
Poster
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz
Poster
2023 ASCO Annual Meeting
TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.
First Author: Rachel M. Layman
Poster
2022 ASCO Annual Meeting
Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.
First Author: Elgene Lim